FDA expands Organon's TOFIDENCE approval for CAR-T and COVID-19 uses

Patients already using tocilizumab for rheumatoid arthritis and juvenile idiopathic arthritis now have a larger biosimilar brand in the market, and cancer and hospital clinicians gained a new option for some of the sickest inflammatory emergencies. Organon’s TOFIDENCE, the first FDA-approved tocilizumab biosimilar in the United States, received expanded U.S. approval on June 10 for CAR-T cell-induced severe or life-threatening cytokine release syndrome and for hospitalized adults and children age 2 and older with COVID-19 who need steroids and oxygen support, ventilation or ECMO.

The move matters because the newly approved uses are not routine outpatient cases. Cytokine release syndrome can turn life-threatening after CAR-T therapy, a cancer treatment that has become central to blood cancer care, and hospitalized COVID-19 patients with severe inflammation can require fast, well-established anti-inflammatory treatment. TOFIDENCE now covers adults and pediatric patients age 2 and older in both settings, bringing its label closer to the acute-care uses already held by Actemra, Roche’s reference drug.

TOFIDENCE first won U.S. approval in September 2023, when the FDA cleared it for rheumatoid arthritis and juvenile idiopathic arthritis. The agency’s label still lists that initial approval date, and FDA materials said comparative clinical data supported the biosimilar’s approval. With the new supplemental approval, TOFIDENCE now matches Actemra more closely in the hospital and oncology settings where clinicians use IL-6 blockade to blunt dangerous immune reactions.

Organon is making the commercial case in plain terms: more biosimilar adoption could help ease the affordability burden of costly biologic drugs. Jon Martin, the company’s U.S. commercial lead for biosimilars and established brands, called the expansion a “vital step forward” for patients facing CRS and said broader biosimilar use may help reduce the cost pressure tied to high-priced brand biologics. Whether that translates into meaningful savings will depend on how hospitals, insurers and health systems place TOFIDENCE on formularies and negotiate coverage, but the expanded label gives them another lower-cost competitor to consider.

The approval also lands as Organon moves through major corporate change. Sun Pharmaceutical Industries Limited and Organon disclosed a definitive acquisition agreement in late April, valuing Organon at $11.75 billion and setting a cash payout of $14.00 per share for stockholders. For Organon, the expanded TOFIDENCE label strengthens a biosimilars franchise that is increasingly tied to both access and revenue in high-stakes hospital medicine.